Subgroup analyses of the Keynote-177 study of pembrolizumab in MSI CRC suggested that tumors carrying RAS mutations did not have a PFS benefit with PD-1 blockade therapy, whereas no correlation was found with BRAF mutational status [19]. Here, PDCD1 is linked to colorectal carcinoma.